Company Profile
Adamas Pharmaceuticals, Inc
Company Overview
Adamas uses its deep understanding of time-dependent biology to redefine the treatment experience for patients suffering from chronic neurological diseases. Building upon the commercial launch of GOCOVRI TM (amantadine) extended release capsules (previously ADS-5102), the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications and its advancing pipeline of differentiated investigational programs, which includes ADS-5102 in development for the treatment of multiple sclerosis walking impairment; and ADS-4101, a high-dose, modified-release lacosamide in development for the treatment of partial onset seizures in patients with epilepsy, Adamas’ goal is to create and commercialize a new generation of medicines intended to lessen the burden of disease on patients, caregivers and society. Its unique expertise lies in uncovering and mapping the relationship between disease and drug activity to create medicines with therapeutic profiles that match the pattern of disease to drive a highly significant and durable clinical effect. This understanding of time-dependent biological processes informs every innovation, targeting advancement in treatment of chronic neurologic disorders. For more information, please visit www.adamaspharma.com.
Benefits
We offer competitive benefits to enrich the way you live.
Our employees’ effort, teamwork and creativity help make Adamas a great place to build a career, and we are proud to recognize and reward those who live our mission, vision and core values. That’s why we’ve designed a Total Rewards experience that includes a wide-ranging portfolio of compensation, benefits, recognition and well-being programs that support the health, welfare and financial enrichment of our employees and their families.